Inmed Clinpharm

Publikationsliste – Publication List

Fachbuch

Klüglich, Matthias

Arzneimittelentwicklung – Von Target bis Launch

Drug Development – From Target to Launch (German Language)

Editio Cantor Verlag, Aulendorf, 2018

Fachartikel – Journal Publications

  • Klüglich, M. Inauguraldissertation 1991, Ludwig-Maximilian-Universität München: “Die Häufigkeit des Diabetes mellitus im dermatologischen Krankengut” (Professor R. Breit)
  • Middeke M, Klüglich M, Jahn M, Beck B, Holzgreve H. Münch.med.Wschr. 1990;132(48): Praxishypertonie oder permanente Hypertonie? Differentialdiagnose durch 24-Stunden-Blutdruckmessung.
  • Klüglich M, Reder S, Holzgreve H, Middeke M. Münch.med.Wschr. 1991;133(43):640-642: Sporadische adrenomedullläre Hyperplasie mit Hypertonie: ein eigenes Krankheitsbild?
  • Middeke M, Klueglich M, Holzgreve H. Chronobiol Int 1991;8(6):506-10: Chronopharmacology of captopril plus hydrochlorothiazide in hypertension: morning versus evening dosing.
  • Middeke M, Klueglich M, Holzgreve H.Chronobiol Int 1991;8(6):451-9: Circadian blood pressure rhythm in primary and secondary hypertension.
  • Middeke M, Kluglich M, Holzgreve H. Z Kardiol. 1991;80 Suppl 1:17-20: Value of ambulatory 24-hour blood pressure monitoring in diagnosis of mild hypertension.
  • Middeke M, Ruff S, Kluglich M. Z Gesamte Inn Med.1992;47(12):558-61: What does general practice hypertension mean?
  • Kluglich M, Middeke M. Z Kardiol. 1992;81 Suppl 2:33-6: Circadian blood pressure rhythm in hyperthyroidism and primary hyperparathyroidism.
  • Middeke M, Klüglich M.  Fallbeispiele Hypertonie I, , 1993, Georg Thieme Verlag Stuttgart New York
  • Kluglich M, Duelli R, Zoller WG, Middeke M. Imaging 1993;60(3):144-6: Ultrasound of incidental tumors of the adrenal gland and endocrine hypertension.
  • Middeke M, Klüglich M. Geriat. Forsch, 1995;5(3):125-132: Gestörte nächtliche Blutdruckregulation bei Hypertonikern im höheren Lebensalter.
  • Hindmarch I, Evans K, Klueglich M. Poster presentation 41st Annual NCDEU Meeting 2001: Electroencephalography (EEG), cognitive performance, 24-hour body activity and mood-rating after single increasing doses of flibanserin in healthy male volunteers.
  • Klueglich M, Wolters M, Schumacher H, Evans K, Adamus WS. Poster presentation 43rd International Conference DGPT 2002, published in Naunyn Schmiedbergs Arch Pharmacol (2002), 365 (Supp 1): Midwestern, Continental, or „Snack“ Breakfast – Does it Matter? Food-effects on Morning-Dose Pharmacokinetics of a Novel, Centrally Active HT1A agonist/HT2A antagonist.
  • Klueglich M, Rathgen K, Trommeshauser D, Seidler R, Roberts J.  Poster presentation 31st Annual Meeting of the American College of Clinical Pharmacology 2002: Safety, Tolerability, Pharmacokinetic Profile and Pharmacodynamic Characteristics of Sabiporide, a Novel Cardioselective NHE-Inhibitor, after Oral and IV Single Doses in Healthy Male Volunteers.
  • Klüglich M, Scheuerer S, Wallenstein G. Poster presentation 6th Congress of the European Association for Clinical Pharmacology and Therapeutics 2003: Dose Proportionality (7.5mg To 22.5mg) and Food Effect (22.5mg) of Meloxicam Oral Suspension. An Open 4-Way Crossover Trial in Healthy Volunteers.
  • Klueglich M, Iovino M, Gerken F, Tuerck D. Influence of Cimetidine, Compared to Ranitidine, on Renal Tubular Cationic Drug Transport of Tiotropium, a Novel Long-acting Antimuscarinic Bronchodilator. J Clin Pharmacol 2003;43(9):1024 (39)
  • Klueglich M, Ring A, Scheuerer S, Trommeshauser D, Schuijt C, Liepold B, and Berndl G. Ibuprofen Extrudate, a Novel, Rapidly Dissolving Ibuprofen Formulation: Relative Bioavailability Compared to Ibuprofen Lysinate and Regular Ibuprofen, and Food Effect on All Formulations. J Clin Pharmacol 2005 45: 1055
  • Klueglich M, Ring A, Scheuerer S, Schuijt C, Liepold B, Berndl G. Poster presentation 8th Congress of the European Association for Clinical Pharmacology and Therapeutics 2004: Ibuprofen extrudate, a novel, rapidly dissolving ibuprofen formulation: relative bioavailability compared to lysinate and regular ibuprofen, and food effect.
  • Luca Richeldi, Ulrich Costabel, Moises Selman, Dong Soon Kim, David M. Hansell, Andrew G. Nicholson, Kevin K. Brown, Kevin R. Flaherty, Paul W. Noble, Ganesh Raghu, Michèle Brun, Abhya Gupta, Nolwenn Juhel, Matthias Klüglich, and Roland M. du Bois. Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis.  New England Journal of Medicine, 2011;365(12)
  • Nieves Vélez de Mendizábal, Alexander Staab, Hans Günter Schäfer, Dirk Trommeshauser, Christiane Döge, Matthias Klüglich, Juliet Roberts, Iñaki F. Trocóniz. Joint Population Pharmacokinetic/Pharmacodynamic Model for the Heart Rate Effects at Rest and at the End of Exercise for Cilobradine. Pharm Res 2013; 30:1110–1122
  • Ogura T, Taniguchi H, Azuma A, Inoue Y, Kondoh A, Hasegawa A, Bando M, Abe S, Mochizuki Y, Chida K, Klueglich M, Fujimoto T, Okazaki K, Tadayasu Y, Sakamoto W, Sugiyama Y. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2015;45:1382-92
  • Listed As Investigator:

HANE Trial Research Group. Philipp T, Anlauf M, Distler A, Holzgreve H, Michaelis J, Wellek S. Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. BMJ 1997; 19;315(7101): 154-159.

  • Listed As Investigator:

Boyce SW, Bartels C, Bolli R, Chaitman B, Chen JC, Chi E, Jessel A, Kereiakes D, Knight J, Thulin L, Theroux P; GUARD During Ischemia Against Necrosis (GUARDIAN) Study Investigators. Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial infarction in high-risk CABG surgery patients: results of the CABG surgery cohort of the GUARDIAN study. J Thorac Cardiovasc Surg. 2003;126(2): 420-427

  • Klüglich M, Gröschl P, Pfrommer U. Externe Mitarbeiter im Onsite-Monitoring. Pharm Ind 2017; 79(9):1256-1263
  • Klüglich M. Der PIP. Oder: Pädiatrische Studien im Spannungsfeld zwischen medizinischer Notwendigkeit und ethischer Machbarkeit. Pharm Ind 2019; 81(2):169-74
  • Klüglich M. Moderne Arzneimittelentwicklung. Trial and Error or by Design? Pharm Ind 2019; 81(8):1029-35
  • Klüglich M. Moderne Arzneimittelentwicklung. Altruismus oder Ökonomie? Pharm Ind 2019; 81(9):1167-72
  • Klüglich M. Moderne Arzneimittelentwicklung. Schneller, besser, billiger? Pharm Ind 2019; 81(10):1304-9
  • Klüglich M. Moderne Arzneimittelentwicklung. Gibt es ein Erfolgsrezept? Pharm Ind 2019; 81(11):1456-62
  • Klüglich M. Moderne Arzneimittelentwicklung. Quo vadis? Bio, digital und virtuell. Pharm Ind 2019; 82(1): 26-31
  • Klüglich M. Aktuelle Trends im Design klinischer Prüfungen Teil 1. Pharm Ind 2020; 82(11):1408-14
  • Klüglich M. Aktuelle Trends im Design klinischer Prüfungen Teil 2. Pharm Ind 2020; 82(12):1538-45
  • Klüglich M. A Narrative View on Drug Development and Its Ethical Aspects. InTech Open 2025, 1-23. DOI: 10.5772/intechopen.1009250
  • Klüglich M., Santy B., Tanev M., Hristov K., Mincheva T. Patient feasibility as a novel approach for integrating IRT and LCA statistical models into patient-centric qualitative data—a pilot study. Front. Digit. Health 2024; 6:1-15. DOI: doi.org/10.3389/fdgth.2024.1378497
  • Klüglich M. Medizinforschungsgesetz und klinische Forschung. Sinnvolle Ideen, mutige Vorschläge, überfällige Korrekturen. Pharm Ind 2025; 87(3): 265-269
  • Berk A., Klüglich M. Künstliche Intelligenz in der Klinischen Forschung. Pharm Ind 2024; 86(9): 855-858
  • Klüglich M. Onkolytische Viren – auf dem Weg zum Durchbruch. Pharmazeutische Medizin 2025;  27(1): 1-9
  • Klüglich M. Patient-Directed Digital Tools in Clinical Research. Newsletter Nr. 1/2026 der DGPharMed. https://www.dgpharmed.de/